Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.26)
# 1,027
Out of 5,245 analysts
68
Total ratings
53.19%
Success rate
13.93%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $96.95 | +8.30% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $13.88 | +44.09% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $74.21 | +2.41% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $8.12 | +72.41% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $144.41 | -30.75% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $15.55 | +99.36% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $23.68 | -61.99% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $60.57 | -45.52% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $115.06 | +65.13% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $23.43 | -18.91% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $342.37 | +13.91% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $46.18 | +19.10% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $118.95 | -53.76% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $114.96 | +39.18% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $448.28 | +49.46% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $3.81 | +424.93% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,103.09 | +26.92% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.22 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $45.69 | +96.98% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $172.00 | +56.98% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $96.95
Upside: +8.30%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $13.88
Upside: +44.09%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $74.21
Upside: +2.41%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $8.12
Upside: +72.41%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $144.41
Upside: -30.75%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $15.55
Upside: +99.36%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $23.68
Upside: -61.99%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $60.57
Upside: -45.52%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $115.06
Upside: +65.13%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $23.43
Upside: -18.91%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $342.37
Upside: +13.91%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $46.18
Upside: +19.10%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $118.95
Upside: -53.76%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $114.96
Upside: +39.18%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $448.28
Upside: +49.46%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $3.81
Upside: +424.93%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,103.09
Upside: +26.92%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $45.69
Upside: +96.98%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $172.00
Upside: +56.98%